Newly on Gate2Biotech
To the press: Grundfos acquires technology-leader in water disinfection
2.10.2013 | Newly on Gate2Biotech
Francesco Maia, co-founder of ISIA and Allan Skovgaard, Business Development Director, Grundfos Danish based pump giant, Grundfos, acquires Italian company ISIA, who is a leading expert in chlorine dioxide disinfection equipment and technology in water supply, waste water and industrial applications.
to-BBB Presents Clinical Data on Lead Product 2B3-101 (A Potential New Treatment Option for Patients with Brain Cancer)
28.9.2013 | Newly on Gate2Biotech
Leiden, the Netherlands, 26 September 2013 - A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed 2B3-101 and initiated a clinical trial to investigate this new treatment. The Phase I safety results will be presented at the European Cancer Congress 2013 in Amsterdam at...
Cambridge Research Biochemicals acquires rights to novel technology useful for development of gene and drug therapies
20.9.2013 | Newly on Gate2Biotech
Cambridge Research Biochemicals (CRB), a British company specialising in custom supply of research reagents, principally peptides and antibodies for medical research and the Pharmaceutical industry, today announced that it has licensed the rights to a novel and patentable method for parallel assembly of a large number of peptide-therapeutic cargo...
New MultiFlo™ FX Combines Bulk Dispensing and Washing for Improved, Automated Workflows
18.9.2013 | Newly on Gate2Biotech
WINOOSKI VT, USA — BioTek's new MultiFlo™ FX Microplate Dispenser offers up to four independent reagent dispensers and a washer in one compact and modular platform to simplify and automate microplate-based liquid handling processes, thus saving time and reducing reagent costs.
BioTek\'s Cytation3 Awarded SelectScience Drug Discovery Product of the Year!
12.9.2013 | Newly on Gate2Biotech
September 9, 2013, WINOOSKI VT, USA — For the second year in a row, BioTek Instruments was announced as winner of the SelectScience"Scientists' Choice Award for Best Drug Discovery Product". The award was given for BioTek's new Cytation™3 Cell Imaging Multi-Mode Reader, and was announced at ELRIG Drug Discovery in Manchester,...
University of Warwick wins Domainex’s first Discovery STAR Award to Support hunt for new Chagas Disease Treatment
10.9.2013 | Newly on Gate2Biotech
Domainex Ltd., a drug discovery company specialising in translational research support, has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick. This award will give Professor Fulop access to Domainex’s outstanding drug discovery capabilities to support his research for a much-needed...
EU project to find vaccine against ticks
6.9.2013 | Newly on Gate2Biotech
Brussels, 4 September 2013 European Union-funded researchers are launching a five-year project to find a vaccine against ticks to prevent them transmitting the diseases they carry to people they bite. The €3 million project is funded under the Seventh Framework Programme for Research and Technological Development (FP7). The ultimate aim is to cut...
ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with Merck Serono
4.9.2013 | Newly on Gate2Biotech
ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with Merck Serono. As part of the deal, MS Ventures, the corporate venture capital fund of Merck Serono has taken a minority equity stake in the company.
Diagnosis of Parvovirus B19 enhanced with launch of unique highly sensitive molecular assay
10.7.2013 | Newly on Gate2Biotech
The molecular division of DiaSorin has launched the unique, highly sensitive Iam Parvo assay, a rapid quantitative molecular assay for use on the Liaison® Iam instrument. DiaSorin are the global leader in Parvovirus B19 serology testing, and the addition of this molecular assay expands its diagnostic portfolio for this potentially life-threatening...
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
2.7.2013 | Newly on Gate2Biotech
CAMBRIDGE, MA / Martinsried, Germany- June 27, 2013; Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures.
